- Home
- GYRE vs WTTR Comparison
GYRE vs WTTR Comparison
Compare GYRE & WTTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GYRE
- WTTR
- Stock Information
- Founded
- GYRE 2002
- WTTR 2016
- Country
- GYRE United States
- WTTR United States
- Employees
- GYRE N/A
- WTTR N/A
- Industry
- GYRE Biotechnology: Pharmaceutical Preparations
- WTTR Oilfield Services/Equipment
- Sector
- GYRE Health Care
- WTTR Energy
- Exchange
- GYRE Nasdaq
- WTTR Nasdaq
- Market Cap
- GYRE 897.1M
- WTTR 922.1M
- IPO Year
- GYRE N/A
- WTTR 2017
- Fundamental
- Price
- GYRE $8.21
- WTTR $8.34
- Analyst Decision
- GYRE
- WTTR Strong Buy
- Analyst Count
- GYRE 0
- WTTR 4
- Target Price
- GYRE N/A
- WTTR $14.88
- AVG Volume (30 Days)
- GYRE 80.3K
- WTTR 1.0M
- Earning Date
- GYRE 08-11-2025
- WTTR 08-05-2025
- Dividend Yield
- GYRE N/A
- WTTR 3.36%
- EPS Growth
- GYRE N/A
- WTTR N/A
- EPS
- GYRE 0.02
- WTTR 0.32
- Revenue
- GYRE $102,189,000.00
- WTTR $1,458,995,000.00
- Revenue This Year
- GYRE $21.04
- WTTR $2.96
- Revenue Next Year
- GYRE $89.64
- WTTR $4.82
- P/E Ratio
- GYRE $170.09
- WTTR $25.88
- Revenue Growth
- GYRE N/A
- WTTR N/A
- 52 Week Low
- GYRE $6.11
- WTTR $7.20
- 52 Week High
- GYRE $19.00
- WTTR $15.14
- Technical
- Relative Strength Index (RSI)
- GYRE 60.94
- WTTR 35.05
- Support Level
- GYRE $6.62
- WTTR $8.13
- Resistance Level
- GYRE $7.47
- WTTR $9.21
- Average True Range (ATR)
- GYRE 0.46
- WTTR 0.36
- MACD
- GYRE 0.12
- WTTR -0.15
- Stochastic Oscillator
- GYRE 99.09
- WTTR 15.26
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
About WTTR Select Water Solutions Inc.
Select Water Solutions Inc provides sustainable water and chemical solutions to the energy industry. These solutions are supported by the company's critical water infrastructure assets, chemical manufacturing, and water treatment and recycling capabilities. Its reportable segments are Water Services, Water Infrastructure and Chemical Technologies. It generates the majority of its revenue from Water Services segment.